BioMarin, Ascendis Stocks Drop on Rival's Drug Trial News

Key Market Movers

Shares of BioMarin Pharmaceutical and Ascendis Pharma each declined by approximately 6% after competitor BridgeBio Pharma reported positive clinical trial data for its new achondroplasia treatment.

The news introduces a significant new competitor into the market for treatments of this genetic bone growth condition.

Situational Overview

BridgeBio Pharma announced its oral medication, infigratinib, met its primary endpoint in the Phase 3 PROPEL 3 study. The trial demonstrated a superior annualized height velocity compared to placebo, with a mean treatment difference of +2.10 cm/year.

Notably, the drug also achieved the first statistically significant improvement in body proportionality against a placebo in a randomized trial for achondroplasia, a condition affecting an estimated 55,000 people in the U.S. and European Union.

Impact on the Pharmaceutical Market

The positive data presents a direct competitive threat to BioMarin's Voxzogo, which is currently the only FDA-approved treatment for achondroplasia. Similarly, Ascendis Pharma, which has its own treatment under FDA review, saw its shares fall on the news of a potential new market entrant.

BridgeBio’s oral infigratinib could hold a significant convenience advantage over its injectable competitors. The company plans to submit regulatory applications for the drug in the second half of 2026.

Market Outlook

The market is now pricing in a more competitive landscape for achondroplasia treatments. The potential for a highly effective oral option could disrupt the current dominance of injectable therapies, pending successful regulatory review and approval.

FAQ

Q: Why did BioMarin and Ascendis Pharma stocks fall?
A: Their stocks fell due to positive Phase 3 clinical trial results from competitor BridgeBio Pharma for a new oral drug to treat achondroplasia, signaling increased market competition.

Q: What is the significance of BridgeBio's drug?
A: BridgeBio's oral drug, infigratinib, showed strong efficacy and offers a potential convenience advantage over current and upcoming injectable treatments like those from BioMarin and Ascendis.

Source: Investing.com